NasdaqGS - Delayed Quote • USD
REGENXBIO Inc. (RGNX)
At close: May 31 at 4:00 PM EDT
After hours: May 31 at 4:20 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 6 | 5 |
Avg. Estimate | -1.29 | -1.27 | -5.04 | -2.26 |
Low Estimate | -1.41 | -1.43 | -5.61 | -5.49 |
High Estimate | -1.11 | -0.94 | -4.46 | 0.12 |
Year Ago EPS | -1.66 | -1.41 | -6.02 | -5.04 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 7 | 7 |
Avg. Estimate | 24.84M | 27.09M | 111.7M | 299.55M |
Low Estimate | 15.5M | 16M | 63.62M | 80.61M |
High Estimate | 34.7M | 34.7M | 158.27M | 431M |
Year Ago Sales | -- | -- | 90.24M | 111.7M |
Sales Growth (year/est) | -- | -- | 23.80% | 168.20% |
Earnings History
CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
---|---|---|---|---|
EPS Est. | -1.38 | -1.52 | -1.27 | -1.26 |
EPS Actual | -1.66 | -1.41 | -1.43 | -1.38 |
Difference | -0.28 | 0.11 | -0.16 | -0.12 |
Surprise % | -20.30% | 7.20% | -12.60% | -9.50% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -1.29 | -1.27 | -5.04 | -2.26 |
7 Days Ago | -1.28 | -1.26 | -5.02 | -1.58 |
30 Days Ago | -1.22 | -1.17 | -4.53 | -2.19 |
60 Days Ago | -1.22 | -1.17 | -4.53 | -2.19 |
90 Days Ago | -1.13 | -1.05 | -3.89 | -2.71 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | 1 | -- | 1 | 3 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | RGNX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 22.30% | -- | -- | 7.70% |
Next Qtr. | 9.90% | -- | -- | 10.10% |
Current Year | 16.30% | -- | -- | 4.60% |
Next Year | 55.20% | -- | -- | 12.50% |
Next 5 Years (per annum) | 13.60% | -- | -- | 11.29% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
Maintains | Stifel: Buy to Buy | 4/12/2024 |
Initiated | HC Wainwright & Co.: Buy | 3/11/2024 |
Upgrade | RBC Capital: Sector Perform to Outperform | 3/8/2024 |
Maintains | Chardan Capital: Buy to Buy | 3/7/2024 |
Maintains | Barclays: Overweight to Overweight | 3/7/2024 |
Related Tickers
QURE uniQure N.V.
4.9500
+5.77%
ADVM Adverum Biotechnologies, Inc.
7.92
+1.41%
XNCR Xencor, Inc.
23.76
-0.54%
SWTX SpringWorks Therapeutics, Inc.
41.46
-2.70%
REPL Replimune Group, Inc.
5.27
+3.33%
KRYS Krystal Biotech, Inc.
160.05
-0.96%
VYGR Voyager Therapeutics, Inc.
8.40
+3.19%
RARE Ultragenyx Pharmaceutical Inc.
40.14
+3.86%
IONS Ionis Pharmaceuticals, Inc.
37.57
+2.79%
KYMR Kymera Therapeutics, Inc.
32.11
-0.16%